Arginine-pyrimidine conjugates with therapeutic and prophylactic activity in lethal bacterial infections

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 22, 2009, Pages 6317-6318

  Haebich, Dieter ^a   Kroll, Hein Peter ^a   Lerchen, Hans Georg ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Antibacterials; Host pathogen interaction; Immunostimulant; Signal transduction

Indexed keywords

ANTIINFECTIVE AGENT; ARGININE; ARGININE PYRIMIDINE CONJUGATE; CIPROFLOXACIN; PYRIMIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM POSITIVE ASPOROGENOUS ROD-SHAPED BACTERIA; IN VITRO STUDY; MOUSE; NONHUMAN; RETREATMENT; SEPSIS; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ARGININE; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; METHICILLIN RESISTANCE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; STREPTOCOCCAL INFECTIONS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 71049181489     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.090     Document Type: Article

References (20)

1. Walsh C. Nat. Rev. Microbiol. 1 (2003) 65
2. Nathan C. Nature 431 (2004) 899
3. Coates A., Hu Y., Bax R., and Page C. Nat. Rev. Drug Disc. 1 (2002) 895
4. von Nussbaum F., Brands M., Hinzen B., Weigand S., and Häbich D. Angew. Chem., Int. Ed. 45 (2006) 5072
5. Infectious Disease Society of America (IDSA): http://www.idsociety.org.
6. Liu C.-I., Liu G.Y., Song Y., Yin F., Hensler M.E., Jeng W.-Y., Nizet V., Wang A.H.-J., and Oldfield E. Science 319 (2008) 1391
7. Haebich D., and von Nussbaum F. ChemMedChem 3 (2008) 1173
8. Brodsky I.E., and Medzhitov R. Nat. Cell Biol. 11 (2009) 521
9. Ulvestad E. APMIS 117 (2009) 311
10. Fuqua W.C., Winans S.C., and Greenberg E.P. J. Bacteriol. 176 (1994) 269
11. Bassler B.L. Curr. Opin. Microbiol. 2 (1999) 582
12. Schmoll T., Ott M., Oudega B., and Hacker J. J. Bacteriol. 172 (1990) 5103
13. Danese P.N., Snyder W.B., Cosma C.L., Davis L.J.B., and Silhavy T.J. Genes Dev. 9 (1995) 387
14. Keinänen T.A., Järvinen A., Uimari A., Vepsäläinen J., Khomutov A.R., Grigorenko N.A., Hyvönen M.T., Cerrada-Gimenez M., Alhonen L., and Jänne J. Mini Rev. Med. Chem. 7 (2007) 813
15. Lührs P., Schmidt W., Kutil R., Buschle M., Wagner S.N., Stingl G., and Schneeberger A. J. Immunol. 169 (2002) 5217
16. max = 56 μg/mL (30 min after ip application of 100 mg/kg 1b).
17. CFU = colony forming units.
18. In: Zak O., and Sande M.A. (Eds). Handbook of Animal Models of Infection (1999), Academic Press, San Diego, USA
19. Wound infection by Pseudomonas aeruginosa or muscle infection by Streptococcus pyogenes in cyclophosphamide-treated (2 × 100 mg/kg ip on day 4 and day 1 before infection) immunocompromised mice.
20. Compared to 1b, bacteria were more efficiently eliminated from the blood of mice with diketopiperazine 1c. In preliminary studies a superior efficacy in infection models (E. coli, S. aureus) was observed.